Valeant Raises Offer for Salix
16 March, 2015.
Valeant Pharmaceuticals has announced an increase to its offer price to acquire Salix Pharmaceuticals from $158 per share to $173 per share in cash ($11.1 billion total), reports say today.
The revised bid is said to provide around an additional $1 billion in cash to Salix stockholders and represents an increase of about 9.5 percent over the original agreement.
Endo has since announced that it is withdrawing its rival proposal to acquire Salix (at $175 per share/ $45 in cash for each share of Salix).
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.
